2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2743

Treatment Target Status at 6 Months and Long-Term Outcomes at 5 Years: Analysis of Methotrexate-Naïve Patients with Rheumatoid Arthritis
Abstract Number: 3205

Treatment with Abatacept or Rituximab Targets T Follicular Helper Cells in Patients with Primary Sjogren s Syndrome
Abstract Number: 2150

Treatment with Abatacept Prevents Experimental Dermal Fibrosis and Induces Regression of Established Inflammation-Driven Fibrosis
Abstract Number: 1784

Treatment with Belimumab in SLE Does Not Impair Antibody Response to 13-Valent Pneumococcal Conjugate Vaccine
Abstract Number: 463

Treatment with Biologic Agents for RA in Patients with MTX-Associated Lymphoproliferative Disorders
Abstract Number: 580

Treatment with Biologic Agents in Rheumatoid Arthritis and Mortality Risk in Clinical Practice
Abstract Number: 2129

Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Abnormalities of Vascular and Myocardial Function on Cardiac MRI
Abstract Number: 2768

Trend and Factors Associated with Switching Treatment after Initial Anti-TNF Therapy Among Patients with Rheumatoid Arthritis
Abstract Number: 1688

Trends in Hospitalizations and Charges for Ankylosing Spondylitis, 1993-2012
Abstract Number: 41

Trends in Non-Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis: Is There Room for Improvement?
Abstract Number: 3269

Trends in Prevalence of Knee Pain Among US Adults, National Health Interview Survey, 2002-2010
Abstract Number: 474

Trends in the Use of Opiates in Rheumatoid Arthritis (RA) Compared to Non-RA: A Population Based Study in 2003-2012
Abstract Number: 1653

Trends over Time in Achievement of Low Disease Activity Among Biologic Initiators with Rheumatoid Arthritis
Abstract Number: 2791

TREX-1 Variants in Sjögren’s Syndrome Related Lymphomagenesis
Abstract Number: 119

Triage in Chronic Rheumatic Diseases: Quantitative Physician Estimates for Inflammation (Reversible), Damage (Irreversible), and Distress in Patients with Rheumatoid Arthritis, Osteoarthritis, and Fibromyalgia Seen in Usual Care

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].